Lisa Sammaritano, MD: Rheumatic Diseases in Pregnant Patients

Video

An expert discusses the risks that rheumatic diseases pose for pregnancies as well as the conversations rheumatologists need to have with their patients.

Patients with rheumatic diseases are likelier to have complications during pregnancies than the general population. Rheumatologists, therefore, must be aware of the risks these diseases pose for this specific patient population.

In an interview with HCPLive®, Lisa Sammaritano, MD, Rheumatologist at Weill Cornell Medicine and Hospital for Special Surgery, discussed how rheumatology disorders may influence patients and physician decisions before, during, and after pregnancies.

Rheumatologists have a critical responsibility to evaluate these diseases and determine the best treatment or monitoring approach for such patients. Some courses of action may be encouraging the use of contraception, especially for individuals not planning for a pregnancy, or delaying pregnancy until any active diseases have been treated or managed. 

“It’s almost a universal finding in this area that having any active rheumatic disease prior to or at the moment of conception does increase risk, both maternal and pregnancy related.” Sammaritano said.

Another important consideration is the medication that is prescribed to treat the rheumatic disease. While some medicines are considered safe during pregnancies, other common therapies are potentially teratogenic.

It is thus important for the patient to be aware of their medication use before and during pregnancies, and healthcare providers must halt any potentially concerning treatments in a timely manner.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.